Evaluation of the safety and efficacy of the Cobra PzF NanoCoated coronary stent in routine, consecutive, prospective, and high‐risk patients: The e‐Cobra study. Issue 1 (17th June 2020)

• Record Type: Journal Article
• Authors: Maillard, Luc; de Labriolle, Axel; Brasselet, Camille; Faurie, Benjamin; Durel, Nicolas; de Poli, Fabien; Bosle, Sébastien; Madiot, Hend; Berland, Jacques; Belle, Loic
• Is Part Of: Catheterization and cardiovascular interventions. Volume 98:Issue 1(2021)
• Page Start: 45
• Page End: 54
• Publication Date: 2020-06-17
• Subjects: Cobra PzF stent -- Polyzene‐F -- stent; Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.29065
• Languages: English
• ISSNs: 1522-1946

Abstract

Abstract: Background: The Cobra PzF coronary stent is cobalt chromium with flat thin struts, nano‐coated with Polyzene‐F that enhance rapid reendothelialization and reduce the risk of stent thrombosis and restenosis. It is designed to overcome shortfalls of BMS and DES in patients requiring short DAPT duration. Aims: To report procedural and 1‐year clinical outcomes following Cobra PzF stent implantation in routine practice PCI. Methods: e‐Cobra registry is a multicenter prospective study to evaluate Cobra PzF stent in routine practice in patients deemed appropriate for short DAPT after PCI. The primary endpoint was MACE rate at 12 months (Cardiac death, MI, TLR). The secondary endpoint was definite stent thrombosis at 12 months. Results: Among 940 patients (72% men, 72.8 ± 13.4 years) with multiple co‐morbidities, 47% had acute coronary syndromes, and 62% were defined as high bleeding risk. A total of 1, 229 lesions were treated with 1, 314 stents. 36% of patients had lesion type B2 or C classification. Angiographic success was achieved in all cases. One‐year follow‐up was available for 97% of patients. The primary endpoint occurred in 9.0% of patients, including cardiac death 3.7%, MI 4.8%, and TLR 4.3%. Definite stent thrombosis occurred in six out of 915 (0.7%). Conclusion: The Cobra PzF stent was safe and effective in routine practice patients and seems feasible in situations when short DAPT or Mono Antiplatelet Therapy (MAPT) is needed. One‐year follow‐up was associated with satisfactory clinical outcomes and validate previously reported data.